Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Ester doai
Reexamination Certificate
2005-03-16
2010-12-14
Fay, Zohreh A (Department: 1627)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Ester doai
C514S573000
Reexamination Certificate
active
07851504
ABSTRACT:
A composition comprising from 0.005% to 0.02% bimatoprost by weight and from 100 ppm to 250 ppm benzalkonium chloride, wherein said composition is an aqueous liquid which is formulated for ophthalmic administration is disclosed herein.A method which is useful in treating glaucoma or ocular hypertension related thereto is also disclosed herein.
REFERENCES:
patent: 4128577 (1978-12-01), Nelson
patent: 4543353 (1985-09-01), Faustini
patent: 4812457 (1989-03-01), Narumiya
patent: 5474979 (1995-12-01), Ding et al.
patent: 6596765 (2003-07-01), Ueno
patent: 6646001 (2003-11-01), Hellberg et al.
patent: 6743439 (2004-06-01), Castillo et al.
patent: 2005/0004074 (2005-01-01), Lyons et al.
patent: 2498233 (2004-03-01), None
patent: 0098141 (1984-11-01), None
patent: 2239458 (1973-07-01), None
patent: S49-69636 (1974-07-01), None
patent: S62215537 (1987-09-01), None
patent: WO2004/133119 (2004-02-01), None
Bito, L.Z. & Baroody, R.A., The Ocular Pharmacokinetics of Eicosanoids and Their Derivatives . . . , 44 Exp. Eye Res. 217-26 (1987).
Pfeiffer, N., New Development in Glaucoma Drug Therapy, 89 Ophthalmologe W1-W13 (1992).
Schumer, Robert A., MD, PhD & Podos, Steven M.,MD, Medical Treatment of Glaucoma, 2 Ophthalmology 140-50 (1991).
Woodford Roger, PhD & Barry, Brian W., PhD, Penetration Enhancers and the Percutaneous Absorption of Drugs: An Update, 5(3) J. Toxicology.—Cut. & Ocular Toxicology 167-77.
Faulkner, R., Aqueous Humor Concentrations of Bimatoprost Free Acid, Bimatoprost and Travoprost . . . , 26 Journal of Ocular Pharmacology and Therapeutics, 147-156 (2010).
Camras, Carl B., Detection of the Free Acid of Bimatoprost in Aqueous Humor Samples from Human Eyes . . . , 111 Ophthamology 2193-2198 (2004).
Cantor, Louis B., Levels of bimatoprost acid in the aqueous humor after bimatoprost treatment . . . , 91 Br J Ophthalmol 629-632 (2007).
Noecker, Robert J.,Corneal and Conjunctival Changes Caused by Commonly Used Glaucoma Medications, Cornea, vol. 23, No. 5, 490-496 (Jul. 2004).
Kaur, I.P.,Penetration enhancers and ocular bioadhesives: Two new avenues for ophthalmic drug delivery, Drug Development and Industrial Pharmacy, 28(4), 353-369 (2002).
Chang Chin-Ming
Chang James N.
Chang-Lin Joan-En
Jordan R. Scott
Schiffman Rhett M.
Allergan Inc.
Ene Doina G.
Fay Zohreh A
Forrestal Kevin J.
Wurst John E.
LandOfFree
Enhanced bimatoprost ophthalmic solution does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Enhanced bimatoprost ophthalmic solution, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Enhanced bimatoprost ophthalmic solution will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4158713